The first generic versions of atomoxetine used for treating attention-deficit/hyperactivity disorder (ADHD) in children and adults have been approved.
A selective norepinephrine reuptake inhibitor, atomoxetine received FDA approval in 2002. Eli Lilly and Company of Indianapolis, Indiana, has marketed the drug as Strattera. Generic versions in various dosages will be manufactured by Apotex Inc of Toronto, Ontario, Canada; Teva Pharmaceuticals USA Inc of North Wales, Pennsylvania; Aurobindo Pharma Limited of Hyderabad, India; and Glenmark Pharmaceuticals Limited of Mumbai, India.
Voelker R. Generic ADHD Drug. JAMA. 2017;318(3):232. doi:10.1001/jama.2017.8439